| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ather Munee. Pharmacotherapy of Acute Bipolar Depression in Adults: An Evidence Based Approach. Korean journal of family medicine. vol 37. issue 3. 2016-06-09. PMID:27274384. |
in the treatment of acute bipolar depression in adults, a comprehensive appraisal of the extant literature reveals that among mood stabilizers, the most robust proof of efficacy exists for divalproex sodium; while atypical antipsychotics, which include olanzapine, quetiapine, lurasidone, and cariprazine, are also effective, as demonstrated in controlled trials. |
2016-06-09 |
2023-08-13 |
Not clear |
| Antony Loebel, Jane Xu, Jay Hsu, Josephine Cucchiaro, Andrei Pikalo. The development of lurasidone for bipolar depression. Annals of the New York Academy of Sciences. vol 1358. 2016-05-23. PMID:26771990. |
the development of lurasidone for bipolar depression. |
2016-05-23 |
2023-08-13 |
Not clear |
| Antony Loebel, Jane Xu, Jay Hsu, Josephine Cucchiaro, Andrei Pikalo. The development of lurasidone for bipolar depression. Annals of the New York Academy of Sciences. vol 1358. 2016-05-23. PMID:26771990. |
the current review summarizes key results of a clinical development program undertaken to characterize the efficacy and safety of lurasidone in patients diagnosed with bipolar depression. |
2016-05-23 |
2023-08-13 |
Not clear |
| Antony Loebel, Jane Xu, Jay Hsu, Josephine Cucchiaro, Andrei Pikalo. The development of lurasidone for bipolar depression. Annals of the New York Academy of Sciences. vol 1358. 2016-05-23. PMID:26771990. |
lurasidone is currently the only treatment for bipolar depression approved in the united states as both a monotherapy and an adjunctive therapy with lithium or valproate. |
2016-05-23 |
2023-08-13 |
Not clear |
| Antony Loebel, Jane Xu, Jay Hsu, Josephine Cucchiaro, Andrei Pikalo. The development of lurasidone for bipolar depression. Annals of the New York Academy of Sciences. vol 1358. 2016-05-23. PMID:26771990. |
the approval of lurasidone expands available treatment options for patients with bipolar depression and provides a therapy with an overall favorable risk-benefit profile. |
2016-05-23 |
2023-08-13 |
Not clear |
| Antony Loebel, Cynthia Siu, Krithika Rajagopalan, Andrei Pikalov, Josephine Cucchiaro, Terence A Kette. Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study. Journal of affective disorders. vol 186. 2016-05-03. PMID:26363720. |
recovery in bipolar depression: post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study. |
2016-05-03 |
2023-08-13 |
Not clear |
| Antony Loebel, Cynthia Siu, Krithika Rajagopalan, Andrei Pikalov, Josephine Cucchiaro, Terence A Kette. Recovery in bipolar depression: Post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study. Journal of affective disorders. vol 186. 2016-05-03. PMID:26363720. |
in this post-hoc analysis, rates of remission and recovery were evaluated in patients with bipolar depression treated with lurasidone. |
2016-05-03 |
2023-08-13 |
Not clear |
| Krithika Rajagopalan, Elizabeth Dansie Bacci, Kathleen W Wyrwich, Andrei Pikalov, Antony Loebe. The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial. International journal of bipolar disorders. vol 4. issue 1. 2016-03-01. PMID:26928122. |
the direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial. |
2016-03-01 |
2023-08-13 |
Not clear |
| Krithika Rajagopalan, Elizabeth Dansie Bacci, Kathleen W Wyrwich, Andrei Pikalov, Antony Loebe. The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial. International journal of bipolar disorders. vol 4. issue 1. 2016-03-01. PMID:26928122. |
the objective of this study was to assess the independent, direct effect of lurasidone treatment on functioning improvement, and examine the indirect effect of lurasidone treatment on functioning improvement, mediated through improvements in depression symptoms. |
2016-03-01 |
2023-08-13 |
Not clear |
| Antony Loebel, Leslie Citrom. Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych bulletin. vol 39. issue 5. 2016-01-12. PMID:26755968. |
lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. |
2016-01-12 |
2023-08-13 |
Not clear |
| Mauro Giovanni Carta, Maria Francesca Moro, Antonio E Nardi, Joseph R Calabres. Potential use of lurasidone for the treatment of bipolar psychosis. Expert opinion on investigational drugs. vol 24. issue 4. 2015-11-13. PMID:25633339. |
lurasidone is one such sga, which is currently approved as a monotherapy for bipolar i depression (bpid) and as an add-on therapy for acute schizophrenia. |
2015-11-13 |
2023-08-13 |
Not clear |
| L Samalin, M Ben Gharbia, M Garnier, P-M Llorc. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]. L'Encephale. vol 40. issue 6. 2015-09-21. PMID:25453735. |
other therapeutic perspectives of lurasidone have been assessed, in particular in bipolar depression. |
2015-09-21 |
2023-08-13 |
Not clear |
| Rachel Franklin, Sam Zorowitz, Andrew K Corse, Alik S Widge, Thilo Deckersbac. Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatric disease and treatment. vol 11. 2015-08-28. PMID:26316760. |
lurasidone for the treatment of bipolar depression: an evidence-based review. |
2015-08-28 |
2023-08-13 |
Not clear |
| Rachel Franklin, Sam Zorowitz, Andrew K Corse, Alik S Widge, Thilo Deckersbac. Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatric disease and treatment. vol 11. 2015-08-28. PMID:26316760. |
lurasidone is a drug in the benzisothiazole class approved by the us food and drug administration in june 2013 for the acute treatment of bipolar depression. |
2015-08-28 |
2023-08-13 |
Not clear |
| Rachel Franklin, Sam Zorowitz, Andrew K Corse, Alik S Widge, Thilo Deckersbac. Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatric disease and treatment. vol 11. 2015-08-28. PMID:26316760. |
preliminary findings from two recent double-blinded clinical trials suggest that lurasidone is efficacious in treating bipolar i depression, with clinical effects manifesting as early as the first 2-3 weeks of treatment (as measured by the montgomery-Åsberg depression rating scale and clinical global impressions scale for use in bipolar illness). |
2015-08-28 |
2023-08-13 |
Not clear |
| Rachel Franklin, Sam Zorowitz, Andrew K Corse, Alik S Widge, Thilo Deckersbac. Lurasidone for the treatment of bipolar depression: an evidence-based review. Neuropsychiatric disease and treatment. vol 11. 2015-08-28. PMID:26316760. |
lurasidone holds clinical potential as a novel, efficacious pharmacological treatment for bipolar depression. |
2015-08-28 |
2023-08-13 |
Not clear |
| Roger S McIntyre, Josephine Cucchiaro, Andrei Pikalov, Hans Kroger, Antony Loebe. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. The Journal of clinical psychiatry. vol 76. issue 4. 2015-06-29. PMID:25844756. |
lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. |
2015-06-29 |
2023-08-13 |
Not clear |
| Roger S McIntyre, Josephine Cucchiaro, Andrei Pikalov, Hans Kroger, Antony Loebe. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. The Journal of clinical psychiatry. vol 76. issue 4. 2015-06-29. PMID:25844756. |
the aim of this post hoc analysis was to evaluate the efficacy and safety of lurasidone in the treatment of patients with bipolar depression presenting with mixed features. |
2015-06-29 |
2023-08-13 |
Not clear |
| Radhika Bawa, Jonathan R Scarf. Lurasidone: a new treatment option for bipolar depression-a review. Innovations in clinical neuroscience. vol 12. issue 1-2. 2015-04-08. PMID:25852975. |
recently, lurasidone was approved to treat bipolar depression either as monotherapy or adjunctively with lithium or valproate. |
2015-04-08 |
2023-08-13 |
Not clear |
| Leslie Citrom. Treatment of bipolar depression: making sensible decisions. CNS spectrums. vol 19 Suppl 1. 2015-02-26. PMID:25407667. |
at present, there are only 3 approved medication treatments for bipolar depression: olanzapine/fluoxetine combination, quetiapine (immediate or extended release), and lurasidone (monotherapy or adjunctive to lithium or valproate). |
2015-02-26 |
2023-08-13 |
Not clear |